The SURPASS-ET trial (NCT04285086) is underway to assess the efficacy and safety of ropeginterferon alfa-2b as a second-line treatment for patients with high-risk essential thrombocythemia (ET) who are resistant to or intolerant of hydroxyurea. This Phase III, open-label, multicenter, global, randomized, active-controlled trial compares ropeginterferon alfa-2b with anagrelide, an approved second-line option.
Addressing Unmet Needs in ET Treatment
Essential thrombocythemia is characterized by an elevated platelet count, increasing the risk of thrombosis and bleeding. Hydroxyurea is a common first-line treatment, but resistance or intolerance can develop. Anagrelide is an alternative, but concerns about disease transformation may limit its long-term use. Ropeginterferon alfa-2b, a long-acting interferon with a favorable safety profile in polycythemia vera, offers a potential new therapeutic avenue.
Study Design and Objectives
The SURPASS-ET trial evaluates the safety, efficacy, tolerability, and pharmacokinetics of ropeginterferon alfa-2b compared to anagrelide in ET patients who have failed hydroxyurea treatment. The trial aims to determine if ropeginterferon alfa-2b can effectively reduce the risk of thrombosis and disease progression in this high-risk population. The outcomes of this study could significantly impact the treatment landscape for ET, providing a much-needed alternative for patients who cannot tolerate or do not respond to existing therapies.
